

THE LANCET Oncology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Siegel AB, Stebbing J. Quackery: Milk thistle: early seeds of potential.
Lancet Oncol 2013; **14**: 929–30.

Quackery: milk thistle

1. Sayyah M, Boostani H, Pakseresht S, et al. Comparison of *Silybum marianum* (L.) Gaertn. with fluoxetine in the treatment of obsessive-compulsive disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 2010; **34**: 362–65.
2. Greenlee H, Abascal K, Yarnell E, et al. Clinical applications of *Silybum marianum* in oncology. *Integr Cancer Ther* 2007; **6**: 158–65.
3. Pugh B. The best hangover remedies tested. *The Telegraph* (London), Dec 5, 2008. <http://www.telegraph.co.uk/health/3568094/The-best-hangover-remedies-tested.html>
4. Enjalbert F, Rapior S, Nouguiet-Soule J, et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. *J Toxicol Clin Toxicol* 2002; **40**: 715–57.
5. Ferenci P, Scherzer TM, Kerschner H, et al. Silybinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. *Gastroenterology* 2008; **135**: 1561–67.
6. Fried MW, Navarro VJ, Afdhal N, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. *JAMA* 2012; **308**: 274–82.
7. Payer BA, Reiberger T, Rutter K, et al. Successful HCV eradication and inhibition of HIV replication by intravenous silybinin in an HIV-HCV coinfecting patient. *J Clin Virol* 2010; **49**: 131–33.
8. Ladas EJ, Kroll DJ, Oberlies NH, et al. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). *Cancer* 2010; **116**: 506–13.
9. Siegel AB, Narayan R, Rodriguez R, et al. A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. *Integr Cancer Ther* 2013; published online June 11. DOI:10.1177/1534735413490798.
10. Flaig TW, Gustafson DL, Su LJ, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. *Invest New Drugs* 2007; **25**: 139–46.
11. Heaney ML, Gardner JR, Karasavvas N, et al: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. *Cancer Res* 2008; **68**: 8031–38.